BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
61.99
+0.65 (1.06%)
After Hours: 61.99 0.00 (0.00%)
Apr 22, 5:08PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 61.81 - 63.42
52 week 53.53 - 84.25
Open 62.84
Vol / Avg. 0.00/1.74M
Mkt cap 8.90B
P/E     -
Div/yield     -
EPS -1.28
Shares 143.62M
Beta 0.85
Inst. own 100%
May 1, 2014
Q1 2014 BioMarin Pharmaceutical Inc. Earnings Conference Call - 5:00PM EDT - Add to calendar
May 1, 2014
Q1 2014 BioMarin Pharmaceutical Inc. Earnings Release - 4:00PM EDT - Add to calendar
Mar 12, 2014
BioMarin Pharmaceutical Inc. at Barclays Healthcare Conference
Mar 4, 2014
BioMarin Pharmaceutical Inc. at Cowen Health Care Conference
Feb 26, 2014
Q4 2013 BioMarin Pharmaceutical Inc. Earnings Release
Feb 26, 2014
BioMarin Pharmaceutical Inc. at RBC Capital Markets Healthcare Conference
Feb 25, 2014
BioMarin Pharmaceutical Inc. at Citi Global Healthcare Conference
Feb 18, 2014
BioMarin Pharmaceutical Inc. Conference Call to Discuss Preliminary Q4 2013 results and FDA Approval of VIMIZIM T
Feb 17, 2014
Preliminary Q4 2013 BioMarin Pharmaceutical Inc. Earnings Release
Feb 13, 2014
BioMarin Pharmaceutical Inc. at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -42.21% -32.15%
Operating margin -36.17% -30.81%
EBITD margin - -18.93%
Return on average assets -12.85% -9.24%
Return on average equity -19.00% -14.97%
Employees 1,341 -
CDP Score - -

Address

105 DIGITAL DRIVE
NOVATO, CA 94949
United States - Map
+1-415-5066700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company�s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.

Officers and directors

Pierre Lapalme Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jean-Jacques Bienaime Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 58
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Executive Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Vice President, Chief Accounting Officer, Corporate Controller
Age: 39
Bio & Compensation  - Reuters
Dennis J. Slamon M.D., Ph.D. Director
Bio & Compensation  - Reuters